Zacks: Analysts Anticipate Nektar Therapeutics (NASDAQ:NKTR) Will Announce Quarterly Sales of $25.89 Million

Equities research analysts predict that Nektar Therapeutics (NASDAQ:NKTR) will announce sales of $25.89 million for the current quarter, according to Zacks Investment Research. Six analysts have issued estimates for Nektar Therapeutics’ earnings. The highest sales estimate is $27.40 million and the lowest is $24.50 million. Nektar Therapeutics reported sales of $1.09 billion in the same quarter last year, which indicates a negative year-over-year growth rate of 97.6%. The business is scheduled to issue its next quarterly earnings report on Wednesday, August 14th.

According to Zacks, analysts expect that Nektar Therapeutics will report full-year sales of $107.47 million for the current financial year, with estimates ranging from $104.21 million to $111.92 million. For the next fiscal year, analysts anticipate that the company will post sales of $194.75 million, with estimates ranging from $115.24 million to $310.91 million. Zacks’ sales averages are an average based on a survey of analysts that cover Nektar Therapeutics.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.03. The company had revenue of $28.22 million for the quarter, compared to analyst estimates of $25.45 million. Nektar Therapeutics had a net margin of 55.65% and a return on equity of 37.63%. During the same quarter in the previous year, the business earned ($0.60) earnings per share.

NKTR has been the topic of a number of recent research reports. Cowen set a $200.00 price target on shares of Lululemon Athletica and gave the stock a “buy” rating in a report on Thursday, June 13th. Mizuho reiterated a “buy” rating and set a $81.00 price target on shares of Nektar Therapeutics in a report on Friday, May 24th. BidaskClub lowered shares of Zebra Technologies from a “buy” rating to a “hold” rating in a report on Tuesday, July 16th. Zacks Investment Research lowered shares of Hess Midstream Partners from a “hold” rating to a “sell” rating in a report on Tuesday, May 14th. Finally, ValuEngine lowered shares of Intersect ENT from a “buy” rating to a “hold” rating in a report on Monday, June 3rd. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $68.50.

In related news, CFO Gil M. Labrucherie sold 3,767 shares of the business’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $31.37, for a total value of $118,170.79. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Lutz Lingnau sold 10,000 shares of the business’s stock in a transaction on Monday, July 8th. The shares were sold at an average price of $34.63, for a total transaction of $346,300.00. Following the completion of the transaction, the director now owns 33,200 shares in the company, valued at approximately $1,149,716. The disclosure for this sale can be found here. In the last 90 days, insiders sold 219,949 shares of company stock worth $7,285,900. 4.02% of the stock is owned by company insiders.

A number of hedge funds have recently added to or reduced their stakes in NKTR. Meeder Asset Management Inc. raised its holdings in shares of Nektar Therapeutics by 150.2% during the first quarter. Meeder Asset Management Inc. now owns 798 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 479 shares during the period. Quantamental Technologies LLC acquired a new position in shares of Nektar Therapeutics during the first quarter valued at about $27,000. CSat Investment Advisory L.P. raised its holdings in shares of Nektar Therapeutics by 279.2% during the fourth quarter. CSat Investment Advisory L.P. now owns 1,073 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 790 shares during the period. Gemmer Asset Management LLC raised its holdings in shares of Nektar Therapeutics by 476.8% during the second quarter. Gemmer Asset Management LLC now owns 1,390 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 1,149 shares during the period. Finally, Enterprise Financial Services Corp acquired a new position in shares of Nektar Therapeutics during the first quarter valued at about $67,000. Institutional investors and hedge funds own 92.15% of the company’s stock.

Shares of NASDAQ:NKTR traded down $0.10 during mid-day trading on Friday, reaching $31.97. 1,017,889 shares of the company’s stock were exchanged, compared to its average volume of 1,372,475. The firm has a market cap of $5.57 billion, a price-to-earnings ratio of 8.46 and a beta of 2.74. The firm’s fifty day simple moving average is $33.99. The company has a quick ratio of 14.83, a current ratio of 14.94 and a debt-to-equity ratio of 0.21. Nektar Therapeutics has a twelve month low of $29.22 and a twelve month high of $69.76.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.

Featured Story: What is net income?

Get a free copy of the Zacks research report on Nektar Therapeutics (NKTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.